Fenofibrate Micronized Dosing
For adults with primary hypertriglyceridemia or mixed dyslipidemia, initiate micronized fenofibrate at 160 mg once daily with meals; for severe hypertriglyceridemia (≥500 mg/dL), start at 54-160 mg once daily with a maximum of 160 mg daily. 1
Standard Dosing by Indication
Primary Hypercholesterolemia or Mixed Dyslipidemia
- Initial dose: 160 mg once daily with meals 1
- This represents the standard starting dose for lipid modification in adults with type IIa or IIb dyslipidemia 2
Severe Hypertriglyceridemia (TG ≥500 mg/dL)
- Initial dose range: 54-160 mg once daily with meals 1
- Maximum dose: 160 mg daily 1
- Fenofibrate is a first-line option when triglycerides reach ≥500 mg/dL, especially when ≥1000 mg/dL, to reduce pancreatitis risk 2
The 2026 ACC/AHA guidelines emphasize that fibrates like fenofibrate produce expected triglyceride reductions of 30-50% and are particularly valuable for severe hypertriglyceridemia management 2. Multiple fenofibrate formulations exist with varied dosages (100 mg, 145 mg, 160 mg, 200 mg), but the micronized formulation at 160 mg represents the bioequivalent dose to older 200 mg capsule formulations 3.
Renal Impairment Adjustments
Renal function dictates fenofibrate dosing more than any other factor due to significant drug accumulation and creatinine elevation risk.
Mild to Moderate Renal Impairment (eGFR 30-59 mL/min/1.73 m²)
- Initial dose: 54 mg once daily 4, 1
- Do not exceed 54 mg daily 4
- Monitor renal function (serum creatinine and eGFR) before initiation, within 3 months after starting, and every 6 months thereafter 4
Severe Renal Impairment (eGFR <30 mL/min/1.73 m²)
Monitoring During Treatment
- If eGFR decreases persistently to <30 mL/min/1.73 m² during follow-up, discontinue fenofibrate immediately 4
- Fenofibrate reversibly increases serum creatinine by 15-20% in most patients 3
- In patients with baseline renal insufficiency (creatinine clearance 20-100 mL/min), initiate at the lowest available dose and increase only after re-evaluating renal function and lipid parameters 3, 5
The 2013 ACC/AHA guidelines provide the most explicit renal dosing guidance, stating that fenofibrate should not exceed 54 mg/day when eGFR is 30-59 mL/min/1.73 m² 4. The KDOQI guidelines for CKD patients recommend initiating at 54 mg daily and assessing effects on kidney function before any dose adjustments 5.
Hepatic Impairment
Fenofibrate is contraindicated in active liver disease 1. However, recent evidence suggests nuanced management is possible in specific hepatic conditions:
Active Liver Disease
- Absolute contraindication 1
- Do not initiate fenofibrate
Mild Hepatic Impairment (Child-Pugh A)
- Fenofibric acid exposure increases by approximately 25% compared to healthy individuals 6
- May use standard dosing (160 mg) with close monitoring 6
- Monitor liver function tests (ALT, AST, total bilirubin) at baseline and periodically throughout therapy 1
Advanced Fibrosis/Cirrhosis (F3-F4 fibrosis, including MAFLD)
- Fenofibric acid exposure increases by 60% in F3 fibrosis and 80% in F4 cirrhosis compared to healthy individuals 6
- Consider reduced dosing (48 mg daily) if benefits outweigh risks 6
- Historically contraindicated, but 2025 data suggest fenofibrate 48 mg is well-tolerated in advanced fibrosis with acceptable safety profile 6
- Requires intensive monitoring for hepatotoxicity
Monitoring Requirements
- Measure ALT, AST, and total bilirubin at baseline and periodically during treatment 1
- Discontinue immediately if signs/symptoms of liver injury develop or if elevated enzyme levels persist 1
- Serious drug-induced liver injury, including liver transplantation and death, has been reported with fenofibrate 1
The FDA label maintains the contraindication in active liver disease 1, but emerging evidence from 2025 suggests that carefully selected patients with advanced fibrosis due to metabolic-associated fatty liver disease may tolerate lower doses (48 mg) with appropriate monitoring 6.
Elderly Patients
Dose selection in elderly patients must be based entirely on renal function, not age alone 1.
- Assess eGFR before initiating therapy
- If eGFR ≥60 mL/min/1.73 m²: Use standard dosing (160 mg daily)
- If eGFR 30-59 mL/min/1.73 m²: Reduce to 54 mg daily maximum 4
- If eGFR <30 mL/min/1.73 m²: Do not use fenofibrate 1
Elderly patients face increased risk for myopathy, particularly when fenofibrate is combined with statins 4. The 2013 ACC/AHA guidelines emphasize that elderly patients with diabetes, renal failure, or hypothyroidism have significantly elevated myopathy risk 4.
Pregnancy and Lactation
Fenofibrate is contraindicated in nursing mothers 1.
Pregnancy Considerations
- No formal FDA pregnancy category listed in current labeling 1
- Traditionally discontinued preconception due to theoretical fetal risks
- However, emerging case reports demonstrate fenofibrate use in severe hypertriglyceridemia-induced pancreatitis during pregnancy:
- 200 mg daily used successfully after first trimester in recurrent pancreatitis cases 7, 8
- The 2026 ACC/AHA guidelines state: "In pregnant individuals with severe fasting hypertriglyceridemia (TG ≥500 mg/dL), the use of fibrates (after the first trimester) or high-dose omega-3 ethyl esters is reasonable as an adjunct to lifestyle management to lower TG levels and reduce the risk of pancreatitis" (Class 2a recommendation) 2
Clinical Decision-Making in Pregnancy
- Avoid in first trimester
- After first trimester with TG ≥500 mg/dL: Consider fenofibrate 200 mg daily if maternal pancreatitis risk outweighs theoretical fetal risks 2, 7, 8
- Combine with therapeutic plasma exchange for acute severe hypertriglyceridemia 7, 8
- Requires shared decision-making weighing maternal risks of untreated disease against potential fetal medication risks 8
Lactation
- Absolute contraindication 1
- Do not breastfeed while taking fenofibrate
Important Safety Considerations
Myopathy and Rhabdomyolysis Risk
- Risk increases significantly when fenofibrate is combined with statins, particularly in elderly patients, those with diabetes, renal failure, or hypothyroidism 4, 1
- Gemfibrozil should never be combined with statins due to high rhabdomyolysis risk 4
- Fenofibrate may be considered with low- or moderate-intensity statins only if benefits outweigh risks 4
- Monitor for muscle symptoms and measure creatine kinase if symptoms develop 1
Drug Interactions
- Coumarin anticoagulants: Fenofibrate potentiates anticoagulant effects; reduce warfarin dose and monitor INR closely 1
- Bile acid resins: Administer fenofibrate at least 1 hour before or 4-6 hours after bile acid resins 1
- Immunosuppressants: Use caution with cyclosporine due to increased nephrotoxicity risk 1
Cholelithiasis
- Fenofibrate increases cholesterol excretion into bile, raising gallstone risk 1
- If cholelithiasis is suspected, obtain gallbladder imaging 1
- Contraindicated in patients with existing gallbladder disease 1
Administration
- Must be taken with meals to ensure adequate absorption 1
- Once-daily dosing improves adherence compared to older formulations requiring divided doses
The micronized fenofibrate formulation at 160 mg provides bioequivalence to older 200 mg capsule formulations with improved absorption characteristics, allowing convenient once-daily dosing with meals 9, 10, 11.